IL93094A - Tools containing aromatic and plastic discussions having antiviral activity or their analogues or histories, and an anti-virus method used in the same compound - Google Patents

Tools containing aromatic and plastic discussions having antiviral activity or their analogues or histories, and an anti-virus method used in the same compound

Info

Publication number: IL93094A
Authority: IL; Israel
Prior art keywords: analogs; derivatives; diones; article; hypericin
Prior art date: 1989-01-19

Application number

IL9309490A

Other languages

English (en)

Hebrew (he)

Other versions

IL93094A0 (en

Original Assignee

Univ New York

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-01-19

Filing date

1990-01-18

Publication date

1996-06-18

1990-01-18 Application filed by Univ New York filed Critical Univ New York

1990-11-05 Publication of IL93094A0 publication Critical patent/IL93094A0/xx

1996-06-18 Publication of IL93094A publication Critical patent/IL93094A/en

Links

150000001875 compounds Chemical class 0.000 title claims abstract description 115
230000000840 anti-viral effect Effects 0.000 title claims abstract description 77
238000000034 method Methods 0.000 title claims abstract description 29
241000551547 Dione <red algae> Species 0.000 title claims description 42
241000700605 Viruses Species 0.000 claims abstract description 83
210000004369 blood Anatomy 0.000 claims abstract description 82
239000008280 blood Substances 0.000 claims abstract description 82
239000000203 mixture Substances 0.000 claims abstract description 27
230000000415 inactivating effect Effects 0.000 claims abstract description 13
SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 claims description 100
PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 claims description 88
229940005608 hypericin Drugs 0.000 claims description 88
241000725303 Human immunodeficiency virus Species 0.000 claims description 67
239000013060 biological fluid Substances 0.000 claims description 46
241001430294 unidentified retrovirus Species 0.000 claims description 42
150000003839 salts Chemical class 0.000 claims description 31
239000012530 fluid Substances 0.000 claims description 21
230000000798 anti-retroviral effect Effects 0.000 claims description 19
238000004519 manufacturing process Methods 0.000 claims description 19
241000282414 Homo sapiens Species 0.000 claims description 13
238000003860 storage Methods 0.000 claims description 12
210000002700 urine Anatomy 0.000 claims description 11
241000714260 Human T-lymphotropic virus 1 Species 0.000 claims description 8
BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 claims 10
239000007788 liquid Substances 0.000 claims 1
230000000717 retained effect Effects 0.000 claims 1
239000007787 solid Substances 0.000 claims 1
210000001124 body fluid Anatomy 0.000 abstract description 11
239000010839 body fluid Substances 0.000 abstract description 10
239000000314 lubricant Substances 0.000 abstract description 9
230000001150 spermicidal effect Effects 0.000 abstract description 5
235000015110 jellies Nutrition 0.000 abstract description 3
MPGWGYQTRSNGDD-UHFFFAOYSA-N hypericin Chemical compound OC1=CC(O)=C(C2=O)C3=C1C1C(O)=CC(=O)C(C4=O)=C1C1=C3C3=C2C(O)=CC(C)=C3C2=C1C4=C(O)C=C2C MPGWGYQTRSNGDD-UHFFFAOYSA-N 0.000 description 73
210000004027 cell Anatomy 0.000 description 40
YXBUQQDFTYOHQI-UHFFFAOYSA-N Pseudohypericin Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C=C(C)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=CC(CO)=C14 YXBUQQDFTYOHQI-UHFFFAOYSA-N 0.000 description 25
230000000694 effects Effects 0.000 description 24
230000003612 virological effect Effects 0.000 description 23
239000000523 sample Substances 0.000 description 19
238000012360 testing method Methods 0.000 description 17
102100034349 Integrase Human genes 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
208000031886 HIV Infections Diseases 0.000 description 13
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 13
208000015181 infectious disease Diseases 0.000 description 12
239000010836 blood and blood product Substances 0.000 description 11
229940125691 blood product Drugs 0.000 description 11
210000001175 cerebrospinal fluid Anatomy 0.000 description 11
230000002779 inactivation Effects 0.000 description 10
239000002245 particle Substances 0.000 description 10
210000000582 semen Anatomy 0.000 description 10
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
208000037357 HIV infectious disease Diseases 0.000 description 8
241000598436 Human T-cell lymphotropic virus Species 0.000 description 8
241000713772 Human immunodeficiency virus 1 Species 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 8
150000002632 lipids Chemical class 0.000 description 8
235000018102 proteins Nutrition 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
-1 NP-40 Chemical compound 0.000 description 7
238000003556 assay Methods 0.000 description 7
230000036541 health Effects 0.000 description 7
YDOIFHVUBCIUHF-UHFFFAOYSA-N 9,11,13,16,18,20-hexahydroxy-5,24-dimethyloctacyclo[13.11.1.12,10.03,8.04,25.019,27.021,26.014,28]octacosa-1(26),2,4(25),5,8,10,12,14(28),15(27),16,18,20,23-tridecaene-7,22-dione Chemical compound OC1=CC(O)=C2C(O)=C3C(=O)C=C(C)C4=C5C(C)=CC(=O)C6=C(O)C7=C(O)C=C(O)C8=C7C(=C56)C(=C34)C2=C18 YDOIFHVUBCIUHF-UHFFFAOYSA-N 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
210000003743 erythrocyte Anatomy 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
208000030507 AIDS Diseases 0.000 description 5
241000713340 Human immunodeficiency virus 2 Species 0.000 description 5
230000005540 biological transmission Effects 0.000 description 5
239000003433 contraceptive agent Substances 0.000 description 5
230000002254 contraceptive effect Effects 0.000 description 5
239000008103 glucose Substances 0.000 description 5
230000002489 hematologic effect Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
238000011534 incubation Methods 0.000 description 5
230000002458 infectious effect Effects 0.000 description 5
208000032839 leukemia Diseases 0.000 description 5
230000000670 limiting effect Effects 0.000 description 5
238000012545 processing Methods 0.000 description 5
239000000934 spermatocidal agent Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 5
210000002845 virion Anatomy 0.000 description 5
108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
102100027211 Albumin Human genes 0.000 description 4
108010088751 Albumins Proteins 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
241001494479 Pecora Species 0.000 description 4
230000034303 cell budding Effects 0.000 description 4
230000007910 cell fusion Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
230000001177 retroviral effect Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
101710091045 Envelope protein Proteins 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
229910019142 PO4 Inorganic materials 0.000 description 3
101710188315 Protein X Proteins 0.000 description 3
241000700584 Simplexvirus Species 0.000 description 3
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
230000003466 anti-cipated effect Effects 0.000 description 3
210000001772 blood platelet Anatomy 0.000 description 3
239000011575 calcium Substances 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
239000000470 constituent Substances 0.000 description 3
125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
239000002609 medium Substances 0.000 description 3
229940087419 nonoxynol-9 Drugs 0.000 description 3
229920004918 nonoxynol-9 Polymers 0.000 description 3
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
239000010452 phosphate Substances 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000005855 radiation Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000001568 sexual effect Effects 0.000 description 3
239000000126 substance Substances 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
210000001138 tear Anatomy 0.000 description 3
239000003634 thrombocyte concentrate Substances 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
238000012546 transfer Methods 0.000 description 3
229940116269 uric acid Drugs 0.000 description 3
239000000286 vaginal jelly Substances 0.000 description 3
UUXPVUHOWQPCSC-UHFFFAOYSA-N 1,3,8-trihydroxy-6-methyl-10-(2,4,5-trihydroxy-7-methyl-10-oxo-9h-anthracen-9-yl)-10h-anthracen-9-one Chemical compound C12=CC(C)=CC(O)=C2C(=O)C2=C(O)C=C(O)C=C2C1C1C2=CC(O)=CC(O)=C2C(=O)C2=C(O)C=C(C)C=C21 UUXPVUHOWQPCSC-UHFFFAOYSA-N 0.000 description 2
MGRRGKWPEVFJSH-UHFFFAOYSA-N 10-(10-oxoanthracen-9-ylidene)anthracen-9-one Chemical compound C12=CC=CC=C2C(=O)C2=CC=CC=C2C1=C1C2=CC=CC=C2C(=O)C2=CC=CC=C21 MGRRGKWPEVFJSH-UHFFFAOYSA-N 0.000 description 2
RSGFPIWWSCWCFJ-VAXZQHAWSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O RSGFPIWWSCWCFJ-VAXZQHAWSA-N 0.000 description 2
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
244000118350 Andrographis paniculata Species 0.000 description 2
102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
241000283707 Capra Species 0.000 description 2
102100026735 Coagulation factor VIII Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
241000700721 Hepatitis B virus Species 0.000 description 2
101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
108060003951 Immunoglobulin Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
206010038997 Retroviral infections Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000711975 Vesicular stomatitis virus Species 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
241000713325 Visna/maedi virus Species 0.000 description 2
LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000003443 antiviral agent Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000000721 bacterilogical effect Effects 0.000 description 2
239000012503 blood component Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
229940125846 compound 25 Drugs 0.000 description 2
239000012141 concentrate Substances 0.000 description 2
239000013068 control sample Substances 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
239000004023 fresh frozen plasma Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
239000001963 growth medium Substances 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
UOHUELUXECWLFT-UHFFFAOYSA-N hypericin monocarboxylic acid Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C=C(C)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=CC(C(O)=O)=C14 UOHUELUXECWLFT-UHFFFAOYSA-N 0.000 description 2
WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
102000018358 immunoglobulin Human genes 0.000 description 2
238000010874 in vitro model Methods 0.000 description 2
201000006747 infectious mononucleosis Diseases 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000009533 lab test Methods 0.000 description 2
239000006193 liquid solution Substances 0.000 description 2
210000002751 lymph Anatomy 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
210000003899 penis Anatomy 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
YLILOANQCQKPOD-UHFFFAOYSA-N protohypericin Chemical compound C12=C(O)C=C(O)C(C(C3=C(O)C=C(C=C33)C)=O)=C2C3=C2C3=C1C(O)=CC(O)=C3C(=O)C1=C(O)C=C(C)C=C12 YLILOANQCQKPOD-UHFFFAOYSA-N 0.000 description 2
238000002976 reverse transcriptase assay Methods 0.000 description 2
210000003296 saliva Anatomy 0.000 description 2
230000028327 secretion Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
MQSXZQXHIJMNAF-UHFFFAOYSA-N skyrin Chemical compound O=C1C2=C(O)C=C(C)C=C2C(=O)C2=C1C(O)=CC(O)=C2C1=C(C(=O)C=2C(=C(O)C=C(C=2)C)C2=O)C2=C(O)C=C1O MQSXZQXHIJMNAF-UHFFFAOYSA-N 0.000 description 2
239000000243 solution Substances 0.000 description 2
241000894007 species Species 0.000 description 2
239000000829 suppository Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
230000035899 viability Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
229930182837 (R)-adrenaline Natural products 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
FPROBVXTILSYFA-UHFFFAOYSA-N 1,3,8-trihydroxy-6-methyl-4-(2,4,5-trihydroxy-7-methyl-10-oxo-9H-anthracen-1-yl)-10H-anthracen-9-one Chemical compound Cc1cc(O)c2C(=O)c3c(O)cc(O)c(c3Cc2c1)-c1c(O)cc(O)c2C(=O)c3c(O)cc(C)cc3Cc12 FPROBVXTILSYFA-UHFFFAOYSA-N 0.000 description 1
VYMFQAYLNYQHER-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VYMFQAYLNYQHER-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000032484 Accidental exposure to product Diseases 0.000 description 1
208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 1
208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 1
208000031295 Animal disease Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000713838 Avian myeloblastosis virus Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000714266 Bovine leukemia virus Species 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
241000252983 Caecum Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000713756 Caprine arthritis encephalitis virus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229940126657 Compound 17 Drugs 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000714165 Feline leukemia virus Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
102000015779 HDL Lipoproteins Human genes 0.000 description 1
108010010234 HDL Lipoproteins Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
241000714259 Human T-lymphotropic virus 2 Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
FNQXONDLUBKCKL-UHFFFAOYSA-N Hypericodehydrodianthrone Natural products C12=CC(C)=CC(O)=C2C(=O)C2=C(O)C=C(O)C=C2C1=C1C2=CC(O)=CC(O)=C2C(=O)C2=C(O)C=C(C)C=C21 FNQXONDLUBKCKL-UHFFFAOYSA-N 0.000 description 1
241000546188 Hypericum Species 0.000 description 1
235000017309 Hypericum perforatum Nutrition 0.000 description 1
206010069803 Injury associated with device Diseases 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
LTGPFZWZZNUIIK-LURJTMIESA-N Lysol Chemical compound NCCCC[C@H](N)CO LTGPFZWZZNUIIK-LURJTMIESA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000714177 Murine leukemia virus Species 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
101710197985 Probable protein Rev Proteins 0.000 description 1
101710092601 Protein 7.3 Proteins 0.000 description 1
101710150344 Protein Rev Proteins 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
101150085390 RPM1 gene Proteins 0.000 description 1
108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
108010081734 Ribonucleoproteins Proteins 0.000 description 1
102000004389 Ribonucleoproteins Human genes 0.000 description 1
108010081391 Ristocetin Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
229910006069 SO3H Inorganic materials 0.000 description 1
DRYDKQOPVBDZMQ-UHFFFAOYSA-N Secalonic acid A Natural products COC(=O)C12Oc3ccc(c(O)c3C(=O)C1=C(O)CC(C)C2O)c4ccc5OC6(C(O)C(C)CC(=C6C(=O)c5c4O)O)C(=O)OC DRYDKQOPVBDZMQ-UHFFFAOYSA-N 0.000 description 1
208000036692 Sexual transmission of infection Diseases 0.000 description 1
241000713311 Simian immunodeficiency virus Species 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
108010000499 Thromboplastin Proteins 0.000 description 1
102000002262 Thromboplastin Human genes 0.000 description 1
238000008050 Total Bilirubin Reagent Methods 0.000 description 1
102100023038 WD and tetratricopeptide repeats protein 1 Human genes 0.000 description 1
231100000818 accidental exposure Toxicity 0.000 description 1
239000002253 acid Substances 0.000 description 1
201000006966 adult T-cell leukemia Diseases 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
229940127219 anticoagulant drug Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940124522 antiretrovirals Drugs 0.000 description 1
239000003903 antiretrovirus agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
239000003686 blood clotting factor concentrate Substances 0.000 description 1
238000004820 blood count Methods 0.000 description 1
229960000182 blood factors Drugs 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
210000000234 capsid Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
230000003915 cell function Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229960005188 collagen Drugs 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
239000000306 component Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000011258 core-shell material Substances 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
238000012258 culturing Methods 0.000 description 1
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000000645 desinfectant Substances 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000004205 dimethyl polysiloxane Substances 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
201000010099 disease Diseases 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
229960005139 epinephrine Drugs 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
229940124566 female contraceptive agent Drugs 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
229920002457 flexible plastic Polymers 0.000 description 1
239000006260 foam Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
230000005484 gravity Effects 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
238000005534 hematocrit Methods 0.000 description 1
BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
WYKGKJJOBNISQK-UHFFFAOYSA-N hypericin dicarboxylic acid Chemical compound OC1=CC(O)=C2C(=O)C3=C(O)C=C(C(=O)O)C4=C3C3=C2C1=C(C(O)=CC(O)=C1C2=O)C1=C3C1=C2C(O)=CC(C(O)=O)=C14 WYKGKJJOBNISQK-UHFFFAOYSA-N 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
230000009027 insemination Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
229920000126 latex Polymers 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
238000009593 lumbar puncture Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
MHIGBKBJSQVXNH-IWVLMIASSA-N methacycline Chemical compound C=C([C@H]1[C@@H]2O)C3=CC=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O MHIGBKBJSQVXNH-IWVLMIASSA-N 0.000 description 1
229940042016 methacycline Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
SNQQPOLDUKLAAF-UHFFFAOYSA-N nonylphenol Polymers CCCCCCCCCC1=CC=CC=C1O SNQQPOLDUKLAAF-UHFFFAOYSA-N 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
108700026241 pX Genes Proteins 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
150000002989 phenols Polymers 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
238000000053 physical method Methods 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920000307 polymer substrate Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
238000005086 pumping Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000009877 rendering Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
229950004257 ristocetin Drugs 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
230000005582 sexual transmission Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
229920002994 synthetic fiber Polymers 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012956 testing procedure Methods 0.000 description 1
ARGOFCSACXCMNN-UHFFFAOYSA-N tetracene-2-carboxamide Chemical compound C1=CC=CC2=CC3=CC4=CC(C(=O)N)=CC=C4C=C3C=C21 ARGOFCSACXCMNN-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
229930003799 tocopherol Natural products 0.000 description 1
235000010384 tocopherol Nutrition 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
238000002562 urinalysis Methods 0.000 description 1
239000000522 vaginal cream Substances 0.000 description 1
230000007486 viral budding Effects 0.000 description 1
230000007502 viral entry Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0082—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
- A61L2/0088—Liquid substances
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/14—Topical contraceptives and spermacides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
External Artificial Organs (AREA)
Medicinal Preparation (AREA)

IL9309490A 1989-01-19 1990-01-18 Tools containing aromatic and plastic discussions having antiviral activity or their analogues or histories, and an anti-virus method used in the same compound IL93094A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/299,971 US5149718A (en)	1989-01-19	1989-01-19	Biological fluid purification system

Publications (2)

Publication Number	Publication Date
IL93094A0 IL93094A0 (en)	1990-11-05
IL93094A true IL93094A (en)	1996-06-18

Family

ID=23157110

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9309490A IL93094A (en)	1989-01-19	1990-01-18	Tools containing aromatic and plastic discussions having antiviral activity or their analogues or histories, and an anti-virus method used in the same compound

Country Status (8)

Country	Link
US (2)	US5149718A (fr)
EP (1)	EP0409957A4 (fr)
AU (1)	AU640125B2 (fr)
CA (1)	CA2025662A1 (fr)
ES (1)	ES2029389A6 (fr)
IL (1)	IL93094A (fr)
WO (1)	WO1990007876A1 (fr)
ZA (1)	ZA90358B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5149718A (en) *	1989-01-19	1992-09-22	New York University	Biological fluid purification system
DE3930510A1 (de) *	1989-09-13	1991-03-21	Blutspendedienst Dt Rote Kreuz	Verfahren zur inaktivierung von viren in blut und blutprodukten
EP0500893A4 (en) *	1990-09-04	1993-03-10	Edward Shanbrom	Preservation of blood, tissues and biological fluids
US5316768A (en) *	1990-12-28	1994-05-31	Murdock International Corporation	Pharmaceutical compositions having antiviral activity against human cytomegalovirus
US5300059A (en) *	1991-11-19	1994-04-05	Hydro Slip Technologies Inc.	Bloodbag and method of making same
IL100881A (en) *	1992-02-06	1996-06-18	Porat Michael	Causal drug prevents diseases, devices and methods of using it
ATE189123T1 (de) *	1992-06-30	2000-02-15	Us Health	Verfahren zur herstellung einer schutzsperre gegen virus
US6207107B1 (en)	1992-10-05	2001-03-27	Baxter International Inc.	Steam sterilizable system for inactivating viral contaminants in body fluids
US6248733B1 (en)	1998-01-09	2001-06-19	3M Innovative Properties Company	Method for limiting the growth of microorganisms using metal-containing compounds
US7498156B2 (en)	1998-07-21	2009-03-03	Caridianbct Biotechnologies, Llc	Use of visible light at wavelengths of 500 to 550 nm to reduce the number of pathogens in blood and blood components
US7049110B2 (en)	1998-07-21	2006-05-23	Gambro, Inc.	Inactivation of West Nile virus and malaria using photosensitizers
US7220747B2 (en)	1999-07-20	2007-05-22	Gambro, Inc.	Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer
TW590780B (en)	2000-06-02	2004-06-11	Gambro Inc	Additive solutions containing riboflavin
US7648699B2 (en)	2000-06-02	2010-01-19	Caridianbct Biotechnologies, Llc	Preventing transfusion related complications in a recipient of a blood transfusion
US7985588B2 (en)	2000-06-02	2011-07-26	Caridianbct Biotechnologies, Llc	Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light
US6432396B1 (en)	2000-07-06	2002-08-13	3M Innovative Properties Company	Limiting the presence of microorganisms using polymer-bound metal-containing compositions
RU2187329C1 (ru) *	2000-12-18	2002-08-20	Гапонюк Петр Яковлевич	Средство для смазки презерватива
US6581775B1 (en) *	2001-08-10	2003-06-24	Garo Hagopian	Method of external genital cleansing and prophylactic kit
US8796017B2 (en)	2003-05-21	2014-08-05	Jms Co., Ltd.	Container for preparing serum and regenerative medical process using the same
KR101685722B1 (ko) *	2009-03-31	2016-12-20	킴벌리-클라크 월드와이드, 인크.	접힌 티슈 제품의 리필 카트리지
FR3033576B1 (fr) *	2015-03-13	2018-11-16	Fondation Mediterranee Infection	Methode d'inactivation d'un agent infectieux dans un echantillon biologique
CN117159517A (zh) *	2022-05-26	2023-12-05	天津国际生物医药联合研究院	金丝桃素在制备抗圣路易斯脑炎病毒感染药物中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2707704A (en) *	1951-09-29	1955-05-03	Schenley Ind Inc	Process for the preparation of hypericin
US3874384A (en) *	1971-11-01	1975-04-01	American Hospital Supply Corp	Improved blood storage unit and method of storing blood
US4393871A (en) *	1977-06-27	1983-07-19	Vli Corporation	Vaginal device
US4180073A (en) *	1977-08-29	1979-12-25	Alza Corporation	Device for delivering drug to biological environment
US4405323A (en) *	1981-09-08	1983-09-20	Sidney Auerbach	Sanitary napkin
US4670013A (en) *	1982-12-27	1987-06-02	Miles Laboratories, Inc.	Container for blood and blood components
US4728322A (en) *	1986-02-05	1988-03-01	Menlo Care, Inc.	Adjustable catheter assembly
US4755170A (en) *	1986-12-03	1988-07-05	Golden Theodore A	Venipuncture and cutaneous sealing device and method
AU596272B2 (en) *	1987-02-25	1990-04-26	Trustees Of Columbia University In The City Of New York, The	Method of inhibiting the transmission of aids virus
WO1988009655A1 (fr) *	1987-06-05	1988-12-15	Al Sioufi Habib	Procede et dispositif permettant la desinfection de fluides biologiques et recipient prevu a cet effet
US4872464A (en) *	1987-08-04	1989-10-10	Xtramedics, Inc.	Pubic prophylactic with snap-over shield
US4898891A (en) *	1987-08-07	1990-02-06	Yeda Research And Development Company Ltd.	Antiviral compositions
US4855064A (en) *	1988-01-13	1989-08-08	Viratec, Inc.	Apparatus and method for decontaminating virus-infected body fluids
US4840618A (en) *	1988-04-25	1989-06-20	Marvel Ray D	Medical safety device
JPH01299219A (ja) *	1988-05-25	1989-12-04	Eisai Co Ltd	メンフェゴールからなるヒト免疫不全ウイルス感染予防剤
US4891221A (en) *	1988-11-23	1990-01-02	Edward Shanborm	Whole blood antiviral process and composition
US5149718A (en) *	1989-01-19	1992-09-22	New York University	Biological fluid purification system

1989
- 1989-01-19 US US07/299,971 patent/US5149718A/en not_active Expired - Lifetime
1990
- 1990-01-18 AU AU50851/90A patent/AU640125B2/en not_active Ceased
- 1990-01-18 IL IL9309490A patent/IL93094A/en not_active IP Right Cessation
- 1990-01-18 CA CA002025662A patent/CA2025662A1/fr not_active Abandoned
- 1990-01-18 WO PCT/US1990/000398 patent/WO1990007876A1/fr not_active Ceased
- 1990-01-18 EP EP19900903121 patent/EP0409957A4/en not_active Withdrawn
- 1990-01-18 ZA ZA90358A patent/ZA90358B/xx unknown
- 1990-01-19 ES ES9000155A patent/ES2029389A6/es not_active Expired - Lifetime
1992
- 1992-07-01 US US07/907,080 patent/US5326788A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO1990007876A1 (fr)	1990-07-26
US5326788A (en)	1994-07-05
IL93094A0 (en)	1990-11-05
EP0409957A4 (en)	1993-01-07
ZA90358B (en)	1990-10-31
ES2029389A6 (es)	1992-08-01
AU5085190A (en)	1990-08-13
US5149718A (en)	1992-09-22
AU640125B2 (en)	1993-08-19
EP0409957A1 (fr)	1991-01-30
CA2025662A1 (fr)	1990-07-20

Publication	Publication Date	Title
AU640125B2 (en)	1993-08-19	Biological fluids purification systems
US5484396A (en)	1996-01-16	Method and device for treatment of HIV infections and AIDS
US5419759A (en)	1995-05-30	Apparatus and methods for treatment of HIV infections and AIDS
US4891221A (en)	1990-01-02	Whole blood antiviral process and composition
US4938758A (en)	1990-07-03	Anti-pathogenic blood collection system and method
Allen et al.	1959	Blood transfusions and serum hepatitis: use of monochloroacetate as an antibacterial agent in plasma
AU644216B2 (en)	1993-12-02	Preservation of blood, tissues and biological fluids
JPH03504815A (ja)	1991-10-24	血液浄化システム
JP2005509654A (ja)	2005-04-14	血液の保存に有用な抗病原体組成物
Magnani et al.	1994	Feline immunodeficiency virus infection of macrophages: in vitro and in vivo inhibition by dideoxycytidine-5′-triphosphate-loaded erythrocytes
Kaplan et al.	1987	Inactivation of human immunodeficiency virus by Betadine
US6235239B1 (en)	2001-05-22	Virucidal and bactericidal agent for use in the disinfection of biological fluids
H Chaplin et al.	1952	The effects of a phenothiazine derivative (RP. 3300) on red cell preservation
Klein et al.	1990	Transmission of human immunodeficiency virus type 1 (HIV-1) by exposure to blood: defining the risk
Marchette et al.	1979	Effect of immune status on dengue 2 virus replication in cultured leukocytes from infants and children
Kinchington et al.	1993	Lithium γ‐linolenate‐induced cytotoxicity against cells chronically infected with HIV‐1
Friedman et al.	1995	Reducing the infectivity of blood components what we have learned
Rutan et al.	1992	Incidence of HIV seroconversion in paediatric burn patients
WO1996037242A1 (fr)	1996-11-28	Appareils et procedes de traitement du sang
Herbein et al.	1996	Comparison of p24 measurement by ELISA versus indicator cells for detecting residual HIV infectivity in vitro
Kaboth et al.	1974	Prophylaxis of viral hepatitis
Van Oss	1995	Transfusion immunology and medicine
Sinnatamby et al.	1980	A case of thrombotic thrombocytopaenic purpura surviving for four years.
Váry et al.	1976	Hepatitis and its problems in a haemodialysis unit
Hart	1991	AIDS and the anaesthetist

Legal Events

Date	Code	Title
1996-11-14	FF	Patent granted
1997-03-18	KB	Patent renewed
1999-12-31	NE	Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
2000-12-06	RH	Patent void